Biologic Therapy of Ulcerative Colitis: Infliximab, Adlimumab, Golimumab

Chapter

Abstract

Anti-tumor necrosis factor α (anti-TNF-α) agents pose the latest entry into our arsenal compiled to fight ulcerative colitis (UC), a chronic inflammatory bowel disease for which causes are still elusive. Till now, however, among this class of drugs, only infliximab is authorized for use in UC. Infliximab survived the test of randomized clinical trials and the scrutiny of health authorities around the globe. Infliximab has been incorporated into clinical routine guidelines and is recommended to be used for induction and maintenance of remission in patients with moderately to severely active UC who had failed standard immunosuppressants. Furthermore, infliximab’s potential to induce mucosal healing and to avoid colectomy has been demonstrated. Early results also suggest the clinical efficacy of adalimumab in UC. Further data are awaited, which also applies to golimumab. This chapter summarizes the existing evidence on the efficacy of anti-TNF-α agents in UC and endeavors to discuss it in the context of clinical routine management.

Keywords

Ulcerative colitis Biologics Anti-TNF-α Infliximab Adalimumab 

References

  1. 1.
    Giacomelli R, Passacantando A, Parzanese L, et al. Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn’s disease (CD). Clin Exp Immunol. 1998;111:532–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261–70.PubMedGoogle Scholar
  3. 3.
    Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991;32:913–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994;106:1455–66.PubMedGoogle Scholar
  5. 5.
    Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother. 2001;35:823–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol. 2001;96:2373–81.PubMedCrossRefGoogle Scholar
  7. 7.
    Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr. 2001;113:930–3.PubMedGoogle Scholar
  8. 8.
    Kohn A, Prantera C, Pera A, et al. Anti-tumor necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis. 2002;34:626–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Actis GC, Bruno M, Pinna-Pintor M, et al. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis. 2002;34:631–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther. 2003;18:175–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Mamula P, Markowitz JE, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr. 2004;38:298–301.PubMedCrossRefGoogle Scholar
  12. 12.
    Kohn A, Prantera C, Pera A, et al. Infliximab in the treatment of severe ulcerative colitis: a follow-up study. Eur Rev Med Pharmacol Sci. 2004;8:235–7.PubMedGoogle Scholar
  13. 13.
    Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis. 2005;11:213–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol. 2002;97:2577–84.PubMedCrossRefGoogle Scholar
  15. 15.
    Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomized controlled trial. Gut. 2003;52:998–1002.PubMedCrossRefGoogle Scholar
  17. 17.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.PubMedCrossRefGoogle Scholar
  18. 18.
    Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007;102:794–802.PubMedCrossRefGoogle Scholar
  19. 19.
    Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250–60.PubMedCrossRefGoogle Scholar
  20. 20.
    Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–11.PubMedCrossRefGoogle Scholar
  21. 21.
    Armuzzi A, De Pascalis B, Lupascu A, et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 2004;8:231–3.PubMedGoogle Scholar
  22. 22.
    Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol. 2004;16:1167–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;3:CD005112.Google Scholar
  24. 24.
    Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther. 2007;26:747–56.PubMedCrossRefGoogle Scholar
  26. 26.
    Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49–54.PubMedCrossRefGoogle Scholar
  27. 27.
    Arijs I, Li K, Toedter G, Quintens R, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58:1612–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Selvasekar C, Cima R, Larson D, et al. Effect of Infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204:956–63.PubMedCrossRefGoogle Scholar
  29. 29.
    Shen B. Impact of preoperative infliximab use on postoperative infectious complications in ulcerative colitis: the price we have to pay? Inflamm Bowel Dis. 2008;14:1019–21.PubMedCrossRefGoogle Scholar
  30. 30.
    Mor I, Vogel J, da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51:1202–10.PubMedCrossRefGoogle Scholar
  31. 31.
    Schluender S, Ippoliti A, Dubinsky M, et al. Does Infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007;50:1747–53.PubMedCrossRefGoogle Scholar
  32. 32.
    Ferrante M, D’Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15:1062–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Yang Z, Wu Q, Wu K, Fan D. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther. 2010;15(3):486–92.CrossRefGoogle Scholar
  34. 34.
    Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010;105:1430–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Travis SP, Stange EF, Lémann M, et al. for the European Crohn’s and Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2(1):24–62.PubMedCrossRefGoogle Scholar
  36. 36.
    Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol. 2007;13:2328–32.PubMedGoogle Scholar
  37. 37.
    Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008;28(8):966–72.PubMedCrossRefGoogle Scholar
  38. 38.
    Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009;15:1302–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Barreirode Acosta M, Lorenzo A, DominguezMunoz JE. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J Gastroenterol. 2009;15:3814–6.CrossRefGoogle Scholar
  40. 40.
    Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther. 2010;32(4):522–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Taxonera C, Estellés J, Fernández-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33(3):340–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. Gut. 2011;60(6):780–7 [Epub ahead of print].PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Internal Medicine IIIMedical University of Vienna, Univ.-Klinik für Innere Medizin III, Abteilung Gastroenterologie und HepatologieViennaAustria

Personalised recommendations